Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE: KMDA) today announced that the Company was granted two key patents related to its novel Alpha-1 Antitrypsin (AAT) product to treat respiratory diseases. Kamada was granted Russian Patent No. 2472524, entitled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and an additional Australian Patent No. 2007213344 (co-owned with PARI PHARMA GMBH), entitled “Pulmonary delivery of Alpha-1 proteinase inhibitor.”
Help employers find you! Check out all the jobs and post your resume.
